Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2022-06-09 Capital/Financing Update
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
[기재정정]투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서' (Investment Prospectus) which is a formal regulatory filing required for securities offerings (in this case, convertible bonds). It includes a '정정신고' (Amendment Report) header, indicating it is an update to a previously filed prospectus. In the context of financial filings, a prospectus is a primary disclosure document for capital raising activities. Given the specific categories provided, this document falls under the 'Proxy Solicitation & Information Statement' (PSI) or 'Regulatory Filings' (RNS) if strictly following the provided list, but since it is a formal prospectus for a securities offering, it is best classified as a regulatory filing related to capital structure.
2022-06-09 Korean
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of bonds with warrants (신주인수권부사채 발행결정) and includes a formal 'Correction Report' (정정신고) for previously filed information. This type of filing is a regulatory disclosure concerning capital structure changes and financing activities. In the provided taxonomy, 'CAP' (Capital/Financing Update) is the most accurate category for documents detailing bond issuances, financing, and capital structure adjustments.
2022-06-02 Korean
[발행조건확정]증권신고서(채무증권)
Capital/Financing Update Classification · 98% confidence The document is a '증권신고서(채무증권) 정정신고서' (Amendment to Securities Registration Statement for Debt Securities) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the exercise price for warrants (신주인수권부사채) and provides updated valuation data. This type of regulatory filing regarding capital structure and securities issuance falls under the 'Regulatory Filings' category as it is a formal legal disclosure document required by financial authorities.
2022-06-02 Korean
[기재정정]투자설명서
Investor Presentation Classification · 95% confidence The document is a '정정신고' (Amendment Report) for an '투자설명서' (Prospectus) regarding the issuance of bonds with warrants (BW). It details the finalization of the exercise price ('행사가액 확정') for the warrants. In the context of financial filings, an amendment to a prospectus regarding capital structure changes, specifically the finalization of pricing for securities, falls under capital and financing updates. Since this is a formal regulatory filing detailing the terms of a capital-raising instrument, it is classified as a Capital/Financing Update.
2022-06-02 Korean
신주인수권부사채행사가액결정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement from HLB Life Science regarding the determination of the exercise price for a Bond with Warrant (BW) issuance. It details specific financial terms such as the exercise price, interest rates, and put-option details. This falls under capital structure changes and financing activities, which is categorized as 'CAP' (Capital/Financing Update).
2022-06-02 Korean
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the acquisition of shares in another company (타법인 주식 및 출자증권 양수결정). This type of regulatory filing details the acquisition of a company (Aim Co., Ltd.), the financial terms, the purpose of the acquisition, and the valuation process. It is a formal regulatory disclosure of a significant corporate transaction, which falls under the 'Regulatory Filings' category as it is a specific mandatory disclosure of a material event.
2022-05-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.